The efficacy and safety of reduced-dose docetaxel,cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma |
| |
Authors: | Nuriye Y?ld?r?m Özdemir Hüseyin Abal? Berna Öksüzo?lu Burçin Budakoglu Do?an Uncu Tunç Güler Hatice Odaba?? Nurullah Zengin |
| |
Institution: | 1.Medical Oncology Clinic,Ministry of Health Ankara Research and Training Hospital,Ankara,Turkey;2.Medical Oncology Unit Baskent University Faculty of Medicine,Ankara,Turkey;3.Medical Oncology Clinic,Ministry of Health Abdurrahman Dr Yurtaslan Oncology Research and Training Hospital,Ankara,Turkey;4.Adana Uygulama ve Ara?t?rma Merkezi,Ba?kent üniversitesi T?p Fakültesi,Yüre?ir-Adana,Turkey |
| |
Abstract: | Patients with advanced gastric carcinoma have still had bad prognosis despite advances in the modern treatment era. Docetaxel,
cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases. In this study, we modified the
standard doses of DCF (mDCF) to evaluate the effectiveness and side effects. From July 2005 to July 2008, 37 advanced gastric
cancer patients treated with at least one course of mDCF protocol as first-line treatment were included. The mDCF protocol
included 60 mg/m2 docetaxel and cisplatin for 1 day and 600 mg/m2/day, 5-flourouracil infusion for 5 days, repeated every 3 weeks. No patients used prophylactic granulocte -colony stimulating
factor. Of the patients, 28 were male and nine were female; the median age was 53 (23–65) years. Of them, 83.8% received at
least four courses of chemotherapy and 64.9% completed the preplanned six courses of treatment. Eleven (29.7%) of those patients
who received mDCF in the first-line treatment used the FOLFIRI (5-FU, folinic acit, irinotekan) regimen for the second-line
treatment. Response rates were evaluated according to RECIST criteria in 30 out of 37 patients. The median follow-up time
was 7.1 months. The longest follow-up time was 19.9 months. Two patients (5.4%) had complete response, nine (21.6%) had partial
response, and 14 (37.9%) had stabilized disease; overall, the disease was controlled in 25 patients (64.9%) whereas five patients
(13.5%) had progression. Median time to progression was 6.7 months and overall survival was 10 months. The assessment of patients
for grade 3–4 toxicity revealed that while 5.4% had anemia and 8.1% had neutropenia, 5.4% nausea and 5.4% diarrhea. Neutropenic
fever developed in two patients, requiring hospitalization. G-CSF was used in three patients. Two patients with neutropenic
fever and two with severe anemia (total number 4; 10.8%) received delayed chemotherapy. Dose reduction was required in four
patients (10.8%), one due to neutropenia, one due to nephrotoxicity, and two due to nausea. No patient died due to chemotherapy
toxicity. This retrospective study suggested that mDCF might have comparable efficacy with classical DFC, with better toxicity
profile. However, its small size and retrospective nature should be considered when interpreting the results. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|